ClinicalTrials.gg
Drug

Octreotide clinical trials

Also written Sandostatin, SMS995 and MYCAPSSA™.

Includes 5 studies of Octreotide hydrochloride and 2 studies of Octreotide pamoate.

studies test it
121
open now
5
in phase 3
32
first study started
1995

How each study uses Octreotide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Octreotide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Oct 1988 · SANDOSTATIN · NDA 019667 (FDA, Drugs@FDA)
European Union
2 Dec 2022 · Mycapssa · EMEA/H/C/005826 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Octreotide
43
octreotide acetate
24
Sandostatin LAR
17
Octreotide LAR
12
Octreotide Injection
3

Brand

Sandostatin
18
MYCAPSSA™
2

Development codes

SMS995
5
RVG 18236
1
DP1038
1
SMS 201-995
1

Studies by the year they started

117 studies that test it; most in 2005 (10); 1 more planned to start later

Studies that test Octreotide, by start year
YearStudies
19952
19962
19972
19982
19993
20002
20011
20028
20037
20044
200510
20066
20075
20086
20091
20101
20112
20123
20134
20146
20156
20165
20175
20183
20195
20203
20213
20223
20234
20251
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
16
Phase 2
42
Phase 3
32
Phase 4
25
No phase
13

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 41 · Other 80

Novartis Pharmaceuticals (13) · Novartis (7) · Camurus AB (5) · Endo Pharmaceuticals (4) · Columbia University (3) · Eastern Cooperative Oncology Group (3) · Chiasma, Inc. (3) · Alliance for Clinical Trials in Oncology (3)

Often tested with

Tested in the same studies.

Midodrine (7) · Octreotide Depot Formulation CAM2029 (5) · Glucose (3) · Everolimus (3) · Terlipressin (3) · Pegvisomant (3) · Acetazolamide (2) · Atomoxetine (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Octreotide is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test Octreotide, phase 3 first.

Studies

Open first, then newest update. How each study uses Octreotide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 121

See all 121 studies that test Octreotide →

Given beside what is tested · 32 — Octreotide is usual care or a partner of the new treatment

Showing 20 of 32.

As the comparator · 14 — what is tested is compared with Octreotide

Codes

What other systems call Octreotide · ClinicalTrials.gg INT008456

  • MeSH (NLM) D015282OctreotideConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) RWM8CCW8GPOCTREOTIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 7617Confirmed FDA, Wikidata
  • Wikidata Q419935octreotideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C711OctreotideConfirmed FDA, Wikidata
  • DrugBank DB00104One source Wikidata

Also registered as octreotide acetate (UNII 75R0U2568I · RxNorm 221130).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.